Regular ArticleRegulation of CYP1A and CYP3A mRNAs by Ascorbic Acid in Guinea Pigs☆,☆☆
References (55)
Pharmacol. Ther.
(1990)- et al.
Pharmacol. Ther.
(1990) - et al.
Biochem. Pharmacol.
(1988) - et al.
Chem.-Biol. Interact.
(1981) - et al.
Mutat. Res.
(1989) - et al.
J. Biol. Chem.
(1986) - et al.
Toxicol. Appl. Pharmacol.
(1997) - et al.
Arch. Biochem. Biophys.
(1985) - et al.
Biochim. Biophys. Acta
(1992) - et al.
Biochim. Biophys. Acta
(1992)
Biochim. Biophys. Acta
J. Biol. Chem.
J. Biol. Chem.
J. Biol. Chem.
Biochem. Pharmacol.
Arch. Biochem. Biophys.
Arch. Biochem. Biophys.
Pharmacol. Rev.
Cytochrome P-450
Pharmacogenetics
Crit. Rev. Toxicol.
Proc. Natl. Acad. Sci. USA
Pharmacogenetics
Pharmacol. Rev.
Xenobiotica
Nutr. Rev.
J. Pharmacol. Exp. Ther.
Cited by (20)
Ascorbic acid: Much more than just an antioxidant
2002, Biochimica et Biophysica Acta - General SubjectsMolecular Therapeutic Targets in Tobacco-Induced Lung Pathology
2019, Oxidative Stress in Lung Diseases: Volume 1Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products
2017, Expert Review of Clinical PharmacologyDecreased CYP3A expression and activity in guinea pig models of diet-induced metabolic syndrome: Is fatty liver infiltration involved?
2013, Drug Metabolism and DispositionNutrition and pharmacology: General principles and implications for HIV
2011, American Journal of Clinical NutritionDose of 3-methylcholanthrene enhances vitamin C accumulation and mRNA expression of its transporter in the liver of ODS rats and in HepG2 cells
2011, Journal of Biochemical and Molecular Toxicology
- ☆
The P450 isozymes whose cDNAs are described in this article were named guinea pig CYP3A14, CYP3A15, and CYP3A17 by the P450 nomenclature committee. The sequence data of the guinea pigCYP1A2, CYP3A14, CYP3A15,andCYP3A17cDNAs have been deposited with the GSDB/DDBJ/EMBL/NDBI nucleotide sequence databases under Accession Nos. D50457, D16363, D26487, and D28515, respectively.
- ☆☆
T. OmuraY. IshimuraY. Fujii-Kiriyama, Eds.
- 2
To whom correspondence should be addressed at present address: Laboratory of Drug Discovery Research and Development, Development Therapeutics Program, Division of Cancer Treatment, Diagnosis, and Centers, Building 1052, Room 105, National Cancer Institute–FCRDC, Frederick, MD 21702-1201.
- 3
Present address: Ludwig Institute for Cancer Research, Box 595, S-751 24 Uppsala, Sweden.